Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer

Abstract Background Gemcitabine (GEM) is used as a first-line therapy for patients diagnosed with any stage of pancreatic cancer (PC); however, patient survival is poor because of GEM resistance. Thus, new approaches to overcome GEM resistance in PC are urgently needed. Here, we aimed to establish a...

Full description

Saved in:
Bibliographic Details
Main Authors: Eun-Jeong Jeong, Yuna Roh, Eunsun Jung, Jin-Seong Hwang, Taesang Son, Hyun Seung Ban, Tae-Su Han, Young-Kug Choo, Jang-Seong Kim
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Journal of Biomedical Science
Subjects:
CITED4
BIRC2
Gemcitabine
Pancreatic cancer
Drug resistance
Online Access:https://doi.org/10.1186/s12929-025-01140-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12929-025-01140-y

Similar Items